OncoMatch/Clinical Trials/NCT05952804
IVIG for Infection Prevention After CAR-T-Cell Therapy
Is NCT05952804 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Immune Globulin Infusion (Human), 10% Solution and Anti-CD19 CAR T Cells Preparation for hematologic malignancies.
Treatment: Immune Globulin Infusion (Human), 10% Solution · Anti-CD19 CAR T Cells Preparation — This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immunoglobulin G (IgG) antibodies with donor blood product derived IgG antibodies that may help prevent infection. IgG antibodies are often depleted as a result of CAR-T therapy. Giving immunoglobulin replacement therapy may prevent infectious complications in patients receiving CD19 CAR-T cell therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: CAR-T cell therapy (CD19-CAR T-cell product) — FDA-approved product for hematologic malignancies
Participants will receive an Food and Drug Administration (FDA)-approved CD19-CAR T-cell product for the treatment of hematologic malignancies. Patients receiving an FDA-approved product are eligible even if the product is being administered as part of a clinical trial or expanded access program (e.g., product is 'out of specification'; concomitant anti-tumor treatment such as acalabrutinib)
Cannot have received: bone marrow transplant
SUBSEQUENT INFUSIONS: Receipt of bone marrow transplant (allogeneic or autologous)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Cancer Center · Duarte, California
- Moffitt Cancer Center · Tampa, Florida
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- Oregon Health and Science University (OHSU) Knight Cancer Institute · Portland, Oregon
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05952804 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bone marrow transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify